PH12020500511A1 - Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement - Google Patents

Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement

Info

Publication number
PH12020500511A1
PH12020500511A1 PH12020500511A PH12020500511A PH12020500511A1 PH 12020500511 A1 PH12020500511 A1 PH 12020500511A1 PH 12020500511 A PH12020500511 A PH 12020500511A PH 12020500511 A PH12020500511 A PH 12020500511A PH 12020500511 A1 PH12020500511 A1 PH 12020500511A1
Authority
PH
Philippines
Prior art keywords
lipids
carbon atoms
odd number
nutritional supplement
diseases
Prior art date
Application number
PH12020500511A
Inventor
Yuhong Dong
Shengtang Lin
Chun-Hsiung Chang
Original Assignee
Sunregen Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunregen Healthcare Ag filed Critical Sunregen Healthcare Ag
Publication of PH12020500511A1 publication Critical patent/PH12020500511A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the use of lipids bearing fatty acids with an odd number of carbon atoms as pharmaceuticals or nutritional supplement. In particular, such lipids are used in the treatment and/or prevention of neurodegenerative diseases, optic and retinal degenerative diseases, demyelinating diseases, neuromuscular disorders and muscular dystrophy, stroke, brain or spinal cord nerve injury, amyloid related diseases, but also a functional food or food supplement for anti-aging or life-span prolongation and brain function improvement for human and/or animals.
PH12020500511A 2017-09-12 2020-03-12 Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement PH12020500511A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2017/072849 WO2019052629A1 (en) 2017-09-12 2017-09-12 Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement

Publications (1)

Publication Number Publication Date
PH12020500511A1 true PH12020500511A1 (en) 2021-05-17

Family

ID=59846591

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020500511A PH12020500511A1 (en) 2017-09-12 2020-03-12 Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement

Country Status (5)

Country Link
BR (1) BR112020004023A2 (en)
EA (1) EA202090566A1 (en)
IL (1) IL273069A (en)
PH (1) PH12020500511A1 (en)
WO (1) WO2019052629A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240307339A1 (en) * 2021-06-18 2024-09-19 Sunregen Healthcare Ag Novel compounds for the treatment and prevention of neurological complications of viral infections
JP2023061448A (en) * 2021-10-20 2023-05-02 リファインホールディングス株式会社 Endoplasmic reticulum stress inhibitor, neurodegenerative disease preventing/improving agent, agent for prevention/progression prevention/improvement of dementia, and food product

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02247125A (en) * 1989-03-17 1990-10-02 Koken Kk Inhibitor of malignant tumor cell multiplication
EP1289530B1 (en) * 2000-06-14 2006-10-04 PORTER, William Leslie Lipids for modulating immune response
KR20030096323A (en) * 2001-04-18 2003-12-24 프로메틱 바이오사이언시즈 인코포레이티드 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
CN101879156B (en) * 2009-05-07 2013-01-30 上海医药工业研究院 Medicinal composition and application thereof
EP2519234B1 (en) * 2009-12-30 2017-06-28 Baylor Research Institute Anaplerotic therapy for alzheimer's disease
US20110301238A1 (en) * 2010-06-02 2011-12-08 Borges Karin Seizure related disorders and therapeutic methods thereof
JP6588903B2 (en) * 2013-11-14 2019-10-09 ザ・ユニバーシティ・オブ・クイーンズランド Neurodegenerative disorders, and treatment and diagnostic methods thereof
CN103641713B (en) * 2013-11-15 2015-10-21 浙江大学 The preparation method of monoglyceride derivative and application
WO2015110977A1 (en) * 2014-01-22 2015-07-30 Rolexi Marketing (Pty) Ltd Fatty acid composition and medicinal use thereof
CA3026152A1 (en) * 2016-06-08 2017-12-14 Sunregen Healthcare Ag Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement

Also Published As

Publication number Publication date
WO2019052629A1 (en) 2019-03-21
BR112020004023A2 (en) 2020-09-08
IL273069A (en) 2020-04-30
EA202090566A1 (en) 2020-07-14

Similar Documents

Publication Publication Date Title
MX2018015188A (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement.
WO2018060732A3 (en) Compositions and methods for treating seizure disorders
MX2021000071A (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease.
WO2015128403A3 (en) An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue
MA49339A (en) Oligomer extended insulin-fc conjugates
MX2012011776A (en) Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins.
PH12020500511A1 (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
MX2017008815A (en) Composition containing chitin and digestible proteins.
PH12015502238A1 (en) Neuroprotective effect of carotenoids in brain
MX2019006495A (en) Treatment of neurological diseases.
MX2018002223A (en) Novel insulin derivatives and the medical uses hereof.
EP2560633A4 (en) Intravenous omega-3 fatty acid compositions & method of use
WO2018154118A3 (en) Aromatic compounds which enhance notch signaling, for use in therapy
PH12017501070A1 (en) Peptides and their use in the treatment of skin
MX2017015292A (en) Composition for treating brain lesions.
WO2020039088A3 (en) Aromatic molecules for use in the treatment of pathological conditions
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
WO2019028281A3 (en) Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic delivery
PH12015500049A1 (en) Novel portein material
PH12016501205A1 (en) Catecholamine production accelerator, and therapeutic and preventive agent and therapeutic and preventive food composition for diseases caused by catecholamine deficiency
RU2017123243A (en) COMPOSITION CONTAINING PORIA COCOS SKIN EXTRACT INTENDED FOR PREVENTION, SIMPLIFICATION OF THE CONDITION AND TREATMENT OF NEURODEGENERATIVE DISORDERS
WO2015165964A8 (en) Treatment and prevention of alzheimer's disease (ad)
WO2020039092A3 (en) Aromatic molecules for use in the treatment of pathological conditions
MX358002B (en) Magnetic polyurethane composition for nerve stimulation.
WO2017036488A8 (en) Combination product for assisting with relaxation and sleep